03.09.2020 – 14:00 Merck KGaAMerck to Showcase New Data at ACTRIMS-ECTRIMS MSVirtual2020 Meeting, Furthering Innovation in Multiple Sclerosis Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Company to present 54 abstracts across its MS portfolio - MAVENCLAD® (cladribine tablets), Rebif® (interferon beta-1a) and investigational evobrutinib - New long-term data and real-world evidence further characterise efficacy and safety ... more
18.12.2019 – 14:07 Grünenthal GroupAveritas Pharma Announces FDA Acceptance of sNDA Filing for QUTENZA® (capsaicin) 8% Patch for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Morristown, N.J. (ots) - · PDUFA date set for July 19, 2020 · If approved, QUTENZA would be the first topical treatment with a TRPV1 agonist indicated for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. Averitas Pharma, Inc., a subsidiary of GRT US Holding, Inc. and member of the ... more
20.05.2011 – 16:37 Astellas Pharma Europe LimitedAstellas Receives Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA Staines, England (ots/PRNewswire) - Astellas Pharma Europe Ltd., announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of marketing authorisation for VIBATIV (telavancin hydrochloride) for the ... more